LimandjajaGCNiessenFBScheperRJGibbsS. The keloid disorder: heterogeneity, histopathology, mechanisms and models. Front Cell Dev Biol. 2020;8:360. doi:10.3389/fcell.2020.00360
2.
WalshLAWuEPontesD, et al. Keloid treatments: an evidence-based systematic review of recent advances. Syst Rev. 2023;12(1):42. doi:10.1186/s13643-023-02192-7
3.
DiazATanKHeH, et al. Keloid lesions show increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy. J Eur Acad Dermatol Venereol. 2020;34(4):e161-e164. doi:10.1111/jdv.16097
4.
NguyenJKAustinEHuangAMamalisAJagdeoJ. The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets. Arch Dermatol Res. 2020;312(2):81-92. doi:10.1007/s00403-019-01972-3
5.
TirganMHUittoJ. Lack of efficacy of dupilumab in the treatment of keloid disorder. J Eur Acad Dermatol Venereol. 2022;36(2):e120-e122. doi:10.1111/jdv.17669
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
